LY 3154207

Drug Profile

LY 3154207

Alternative Names: LY3154207

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 03 Mar 2017 Eli Lilly completes a phase I trial in Parkinson's disease in USA (NCT02562768)
  • 01 Mar 2016 Eli Lilly completes a pharmacodynamics phase trial in Healthy volunteers in USA (PO) (NCT02603861)
  • 17 Nov 2015 Eli Lilly plans a pharmacodynamics phase I trial in Healthy male volunteers in USA (PO) (NCT02603861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top